These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 9738982

  • 1. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody.
    Taji H, Kagami Y, Okada Y, Andou M, Nishi Y, Saito H, Seto M, Morishima Y.
    Jpn J Cancer Res; 1998 Jul; 89(7):748-56. PubMed ID: 9738982
    [Abstract] [Full Text] [Related]

  • 2. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
    Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B.
    Cancer Biother Radiopharm; 1997 Jun; 12(3):177-86. PubMed ID: 10851464
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.
    Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I.
    Cell Immunol; 2000 Aug 25; 204(1):55-63. PubMed ID: 11006018
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cytocidal activity of PBL, LAK, and IDEC-C2B8 and expression of HLA class 1, ICAM-1, and CD20 in vincristine-resistant hematologic cell lines.
    Hirose M, Hamano S, Tobinai K, Kuroda Y.
    J Immunother; 1999 May 25; 22(3):237-44. PubMed ID: 10335483
    [Abstract] [Full Text] [Related]

  • 8. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody.
    Maeda T, Yamada Y, Tawara M, Yamasaki R, Yakata Y, Tsutsumi C, Onimaru Y, Kamihira S, Tomonaga M.
    Int J Hematol; 2001 Jul 25; 74(1):70-5. PubMed ID: 11530808
    [Abstract] [Full Text] [Related]

  • 9. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.
    Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R.
    Blood; 1994 Oct 15; 84(8):2457-66. PubMed ID: 7522629
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
    Liu Y, Zheng M, Lai Z, Xiong D, Fan D, Xu Y, Peng H, Shao X, Xu Y, Yang M, Wang J, Liu H, Xie Y, Yang C, Zhu Z.
    Cancer Lett; 2004 Mar 18; 205(2):143-53. PubMed ID: 15036646
    [Abstract] [Full Text] [Related]

  • 11. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
    Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY.
    Cancer Res; 2000 Dec 15; 60(24):7170-6. PubMed ID: 11156427
    [Abstract] [Full Text] [Related]

  • 12. [Apoptosis of human B cell lymphoma Raji cells induced by monovalent anti-CD20 antibody].
    Liu YX, Fan DM, Xiong DS, Xu YF, Shao XF, Xu YS, Peng H, Yang M, Qin L, Zhu ZP, Yang CZ.
    Ai Zheng; 2003 Dec 15; 22(12):1249-53. PubMed ID: 14693045
    [Abstract] [Full Text] [Related]

  • 13. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.
    Anderson DR, Grillo-López A, Varns C, Chambers KS, Hanna N.
    Biochem Soc Trans; 1997 May 15; 25(2):705-8. PubMed ID: 9191187
    [No Abstract] [Full Text] [Related]

  • 14. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.
    Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW.
    Eur J Haematol; 1999 Feb 15; 62(2):76-82. PubMed ID: 10052709
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
    Ma D, McDevitt MR, Barendswaard E, Lai L, Curcio MJ, Pellegrini V, Brechbiel MW, Scheinberg DA.
    Leukemia; 2002 Jan 15; 16(1):60-6. PubMed ID: 11840264
    [Abstract] [Full Text] [Related]

  • 17. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells.
    Selenko N, Maidic O, Draxier S, Berer A, Jäger U, Knapp W, Stöckl J.
    Leukemia; 2001 Oct 15; 15(10):1619-26. PubMed ID: 11587221
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
    Nishida M, Usuda S, Okabe M, Miyakoda H, Komatsu M, Hanaoka H, Teshigawara K, Niwa O.
    Int J Oncol; 2007 Jul 15; 31(1):29-40. PubMed ID: 17549402
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.